- Home
- PRTA vs PPT Comparison
PRTA vs PPT Comparison
Compare PRTA & PPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRTA
- PPT
- Stock Information
- Founded
- PRTA 2012
- PPT 1988
- Country
- PRTA Ireland
- PPT United States
- Employees
- PRTA N/A
- PPT N/A
- Industry
- PRTA Biotechnology: Pharmaceutical Preparations
- PPT Finance Companies
- Sector
- PRTA Health Care
- PPT Finance
- Exchange
- PRTA Nasdaq
- PPT Nasdaq
- Market Cap
- PRTA 346.4M
- PPT 351.7M
- IPO Year
- PRTA N/A
- PPT N/A
- Fundamental
- Price
- PRTA $6.41
- PPT $3.66
- Analyst Decision
- PRTA Buy
- PPT
- Analyst Count
- PRTA 9
- PPT 0
- Target Price
- PRTA $27.67
- PPT N/A
- AVG Volume (30 Days)
- PRTA 1.7M
- PPT 156.1K
- Earning Date
- PRTA 08-07-2025
- PPT 01-01-0001
- Dividend Yield
- PRTA N/A
- PPT 8.84%
- EPS Growth
- PRTA N/A
- PPT N/A
- EPS
- PRTA N/A
- PPT N/A
- Revenue
- PRTA $137,935,000.00
- PPT N/A
- Revenue This Year
- PRTA N/A
- PPT N/A
- Revenue Next Year
- PRTA $122.02
- PPT N/A
- P/E Ratio
- PRTA N/A
- PPT N/A
- Revenue Growth
- PRTA 54.55
- PPT N/A
- 52 Week Low
- PRTA $4.32
- PPT $3.25
- 52 Week High
- PRTA $25.42
- PPT $3.72
- Technical
- Relative Strength Index (RSI)
- PRTA 57.61
- PPT 48.03
- Support Level
- PRTA $5.96
- PPT $3.65
- Resistance Level
- PRTA $6.77
- PPT $3.69
- Average True Range (ATR)
- PRTA 0.36
- PPT 0.03
- MACD
- PRTA 0.14
- PPT -0.00
- Stochastic Oscillator
- PRTA 75.80
- PPT 38.89
About PRTA Prothena Corporation plc
Prothena Corp PLC is a clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including ATTR amyloidosis [Coramitug (PRX004)], Alzheimer's disease (PRX123), Neurodegeneration (PRXPRX019), and Others.
About PPT Putnam Premier Income Trust
Putnam Premier Income Trust is a Massachusetts business trust operating as a non-diversified closed-end management investment company. The fund is currently operating as a diversified fund. Its investment objective is to seek high current income consistent with the preservation of capital by allocating its investments to the U.S. government sector.